Biologic therapies in systemic juvenile idiopathic arthritis

BATU AKAL E. D.

EXPERT OPINION ON ORPHAN DRUGS, cilt.4, sa.6, ss.621-629, 2016 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 4 Sayı: 6
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1080/21678707.2016.1177511
  • Dergi Adı: EXPERT OPINION ON ORPHAN DRUGS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.621-629
  • Hacettepe Üniversitesi Adresli: Hayır

Özet

Introduction: Systemic juvenile idiopathic arthritis (SJIA) is characterized by fever, rash, arthritis, lymphadenopathy, hepatosplenomegaly, and serositis. It is frequently considered an autoinflammatory syndrome. There is interplay between different pro-inflammatory cytokines in SJIA pathogenesis. Sufficient control of inflammation is crucial to prevent complications. Treatment strategies in SJIA have changed dramatically with the introduction of increasing number of biologic agents. These modern drugs have improved the inflammation control and reduced side effects of traditional long-term treatments.